Two major clinical trials have evaluated the effects of the PPARα agonist in diabetic complications and identified as tertiary outcomes that fenofibrate significantly decreased diabetic microvascular complications including retinopathy, nephropathy, and peripheral neuropathy in type 2 diabetic patients [17, 18]. This evidence concerns the gene PPARA and Nephropathy.